John Michael Francis Eusebio
Family · Las Vegas, NVNPI 1518605237
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,683 of the $10,871 with a category attached, or 89.1%. It is spread thinly across 60 manufacturers, the largest accounting for just 8.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $4,408 and has fallen 87.4% since, to $556 in 2025. Among family clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 455 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$916
- AstraZeneca$660
- Merck$590
- Eisai Inc.$563
- Astellas Pharma US Inc$487
- Incyte Corporation$462
- plus $7K from 54 others
What the payments were for
- Food & beverage$9,68389%
- Education$1,18811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,871 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 41 | $578,313 |
| PomalystPomalidomide | 20 | $465,981 |
| RevlimidLenalidomide | 23 | $380,832 |
| KisqaliRibociclib Succinate | 23 | $373,489 |
| Lenalidomide | 27 | $372,721 |
| XtandiEnzalutamide | 21 | $281,147 |
| IbrancePalbociclib | 15 | $236,574 |
| NubeqaDarolutamide | 16 | $233,636 |
| KyprolisCarfilzomib | 22 | $232,378 |
| BrukinsaZanubrutinib | 18 | $223,778 |
| JakafiRuxolitinib Phosphate | 13 | $212,252 |
| AlecensaAlectinib Hcl | 13 | $157,190 |
| XgevaDenosumab | 12 | $35,629 |
| EliquisApixaban | 34 | $21,728 |
| Abiraterone Acetate | 13 | $12,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $660 | $578,31341 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $206 | $465,98120 claims |
| Bristol Myers SquibbRevlimid | $318 | $380,83223 claims |
| NovartisKisqali | $916 | $373,48923 claims |
| Astellas Pharma US IncXtandi | $487 | $281,14721 claims |
| PfizerIbrance, Eliquis | $247 | $258,30249 claims |
| BayerNubeqa | $142 | $233,63616 claims |
| Beigene USA, Inc.Brukinsa | $404 | $223,77818 claims |
| Incyte CorporationJakafi | $462 | $212,25213 claims |
| Genentech USA, Inc.Alecensa | $119 | $157,19013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.
Other family in Las Vegas
- Hollie TylerLas Vegas$118K
- John PhoenixLas Vegas$107K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Erin WilkinsonLas Vegas$43K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Kelly PapeshLas Vegas$28K
- Bernard BlanksLas Vegas$26K
- Hillary DursteinLas Vegas$21K
- Victoria HughesLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.